Immune checkpoint inhibitor-associated sarcoidosis reaction

Abstract

Immune checkpoint inhibitors (ICIs) constitute a class of drugs that stimulate the immune system to fight cancer cells. However, they can also induce immune-related adverse events (irAEs) in various organs, including the kidneys. One of the infrequent irAEs associated with ICIs is sarcoidosis, an inflammatory disease that can impact multiple organs, such as the lungs, skin, and lymph nodes. Sarcoidosis is characterized by the formation of granulomas, clusters of immune cells that can potentially harm tissues. In some cases, ICIs can trigger kidney sarcoidosis, leading to impaired renal function. The mechanism through which ICIs initiate sarcoidosis is believed to involve activating T cells and cytokines that foster inflammation.